New lipid and lipoprotein targets for the treatment of cardiometabolic diseases

Journal of Lipid Research

Volumn 53, Issue 9, 2012, Pages 1719-1721

  Hazen, Stanley L ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANACETRAPIB; BILE ACID; BILE ACID RECEPTOR; BILE ACID SEQUESTRANT; CHOLESTEROL ESTER TRANSFER PROTEIN; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; DALCETRAPIB; DARAPLADIB; EVACETRAPIB; FARNESOID X RECEPTOR; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR TGR5; LIPID; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; PHOSPHOLIPASE A2; RECEPTOR; TORCETRAPIB; UNCLASSIFIED DRUG;

ATHEROSCLEROSIS; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; BILE ACID METABOLISM; BILE ACID SYNTHESIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTASIS; CHOLESTEROL BLOOD LEVEL; DRUG BINDING; DRUG EFFICACY; DRUG ELIMINATION; DRUG TARGETING; DYSLIPIDEMIA; EDITORIAL; ENERGY METABOLISM; ENZYME ACTIVITY; ENZYME INHIBITION; GLUCOSE METABOLISM; HYPERLIPIDEMIA; INFLAMMATION; LIPID COMPOSITION; LIPID METABOLISM; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; OBESITY; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PROTEIN TARGETING; RISK REDUCTION; TREATMENT RESPONSE;

ANIMALS; CARDIOVASCULAR DISEASES; HUMANS; LIPOPROTEINS; METABOLIC DISEASES; MOLECULAR TARGETED THERAPY;

EID: 84864836813     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.E030205     Document Type: Editorial

References (17)

1. Danaei, G., E. L. Ding, D. Mozaffarian, B. Taylor, J. Rehm, C. J. L. Murray, and M. Ezzati. 2009. The preventable causes of death in the United States: comparative risk assessment of dietary, lifestyle, and metabolic risk factors. PLoS Med. 6: e1000058.
2. Chiuve, S. E., T. T. Fung, K. M. Rexrode, D. Spiegelman, J. A. E. Manson, M. J. Stampfer, and C. M. Albert. 2011. Adherence to a low-risk, healthy lifestyle and risk of sudden cardiac death among women. JAMA. 306: 62-69.
3. Wong, N. D., J. Dede, V. H. Chow, K. S. Wong, and S. S. Franklin. 2012. Global cardiovascular risk associated with hypertension and extent of treatment and control according to risk group. Am. J. Hypertens. 25: 561-567.
4. Antithrombotic Trialists' (ATT) Collaboration. 2009. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 373: 1849-1860.
5. Stamler, J., D. Wentworth, and J. D. Neaton. 1986. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screens of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA. 256: 2823-2828. (Pubitemid 17178359)
6. Baigent, C., A. Keech, P. M. Kearney, L. Blackwell, G. Buck, C. Pollicino, A. Kirby, T. Sourjina, R. Peto, and R. Collins, et al. 2005. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 366: 1267-1278.
7. Baigent, C., L. Blackwell, J. Emberson, L. E. Holland, C. Reith, N. Bhala, R. Peto, E. H. Barnes, A. Keech, J. Simes, R. Collins, Cholesterol Treatment Trialists' (CTT) Collaboration. 2010. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 376: 1670-1681.
8. Blaha, M. J., K. Nasir, and R. S. Blumenthal. 2012. Statin therapy for healthy men identified as "increased risk". JAMA. 307: 1489-1490.
9. Steinberg, D., C. K. Glass, and J. L. Witztum. 2008. Evidence mandating earlier and more aggressive treatment of hypercholesterolemia. Circulation. 118: 672-677.
10. Lloyd-Jones, D., R. Adams, M. Carnethon, G. De Simone, T. B. Ferguson, K. Flegal, E. Ford, K. Furie, A. Go, K. Greenlund, et al; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. 2009. Heart disease and stroke statistics-2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 119: 480-486.
11. Porez, G., Prawitt J., Gross B., Staels B. 2012. Bile acid receptors as targets for the treatment of dyslipidemia and cardiovascular diseases. J Lipid Res. 53: 1723-1737.
12. No authors listed. 1984. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA. 251: 351-364.
13. Huang, J. V. Greyson C. R. and Schwartz G. G. 2012. PPAR-γ as a therapeutic target in cardiovascular disease: evidence and uncertainty. J Lipid Res. 53: 1738-1754.
14. Barter, P. J., Rye K. A. 2012. Cholesterol ester transfer protein (CETP) inhibition as a strategy to reduce cardiovascular risk. J Lipid Res. 53: 1755-1766.
15. 2. J Lipid Res. 53: 1767-1782.
16. Kunnen, S., Van Eck M. 2012. Lecithin:cholesterol acyltransferase: old friend or foe in atherosclerosis? J Lipid Res. 53: 1783-1799.
17. Glomset, J. A. 1962. The mechanism of the plasma cholesterol esterification reaction: plasma fatty acid trasferase. Biochim. Biophys. Acta. 65: 128-135.